OncoMatch/Clinical Trials/NCT07796113
Adebrelimab With Famitinib and Chemotherapy as Neoadjuvant Therapy for ESCC
Is NCT07796113 recruiting? Yes, currently enrolling (Sep 2026). This Phase 2 trial studies Adebrelimab + Famitinib + Chemotherapy for esophageal squamous cell carcinoma.
Treatment: Adebrelimab + Famitinib + Chemotherapy — This is a prospective, single-arm, exploratory clinical study enrolling patients with resectable, locally advanced thoracic esophageal squamous cell carcinoma (ESCC) confirmed by histology or cytology. The study aims to evaluate the efficacy and safety of neoadjuvant therapy with adebrelimab in combination with famitinib and chemotherapy in this population. The primary endpoint is the pathological complete response (pCR) rate, with a planned enrollment of 24 patients.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Esophageal Carcinoma
Disease stage
Required: Stage T1B-T2N+, T3-T4A, ANY N
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: radiotherapy for esophageal cancer
No prior anti-tumor therapy for esophageal cancer, including radiotherapy, chemotherapy, or surgery
Cannot have received: chemotherapy for esophageal cancer
No prior anti-tumor therapy for esophageal cancer, including radiotherapy, chemotherapy, or surgery
Cannot have received: surgery for esophageal cancer
No prior anti-tumor therapy for esophageal cancer, including radiotherapy, chemotherapy, or surgery
Lab requirements
Blood counts
ANC ≥ 1.5 × 10⁹/L; Platelet count ≥ 100 × 10⁹/L; Hemoglobin ≥ 90 g/L
Kidney function
Serum creatinine ≤ 1.5 × ULN, or creatinine clearance ≥ 50 mL/min
Liver function
Total bilirubin ≤ 1.5 × ULN; ALT ≤ 2.5 × ULN, AST ≤ 2.5 × ULN
Adequate organ function, defined as follows: ... see inclusion criterion 10
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07796113 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage T1B-T2N+ or T3-T4A, ANY N is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages